The foundation of Pikralida’s success is a team of over 20 highly qualified specialists, who combine interdisciplinary knowledge with extensive experience in research projects for medicinal products at various stages of development. Our experts have successfully executed numerous projects, spanning early-stage clinical trials as well as later-stage development, including generic drug formulations.
Our work is based on efficient project management, enabling the seamless execution of complex research activities, while maintaining the highest quality standards and regulatory compliance. We effectively secure funding and optimize processes, supporting the development of innovative therapies that address the challenges of modern preclinical and clinical research, contributing to advancements in medicine and pharmaceuticals.
Graduate of PhD studies at the Institute of Organic Chemistry of the Polish Academy of Sciences with postdoctoral fellowships in the teams of prof. M. Isobe at University of Nagoya (Japan) and prof. E. J. Corey at Harvard University (USA). Stanisław was working, among other companies, in Procter & Gamble Pharmaceuticals, Avalon Pharmaceuticals, PTC Therapeutics, and ScinoPharm Pharmaceuticals.
From February 2012 to December 2018 he cooperated with OncoArnedi Therapeutics SA as a co-founder and member of the board. As a Head of Development, he was responsible for the design and execution of preclinical and clinical strategies for drug candidates developed by the Company, the conduct of scientific projects covering CMC, preclinical development, obtaining approvals for clinical trials, and also for the designing and supervision of the clinical trials.
Expert with many years of experience in the management of R&D projects, from the phase of design and drug candidate structure optimisation to the establishment of the preclinical and clinical development strategies, and building and management of science teams.
Pharmaceutical scientist with over 15 years of industrial experience. Expert with great experience in the management of research and development projects of innovative and generic drugs. Anna worked in GlaxoSmithKline for several years and after the closure of the Poznań site, she co-founded PozLab sp. z o.o. where she was the President for 8 years. For over 5 years she was managing the Quality and Control Department and held the function of Qualified Person.
From September 2018 to February 2020 Anna worked at OncoArendi Therapeutics S.A. as Head of Drug Development where she was responsible for CMC area and preclinical development of drug candidates.
She is a co-author of many research and development projects conducted based on the fundings provided by NCBR, NCN, European Commission, and FNP organisations.
Lecturer in “Industrial Pharmacy” postgraduate studies carried out by the Pharmaceutical Department of Medical University of Gdańsk.
Graduate of the PhD studies at the Institute of Organic Chemistry of the Polish Academy of Sciences. Joanna worked for three years in the Medical Chemistry Department of Celon Pharma SA where she was responsible for the design and synthesis of drug candidates. From 2015 to 2018 Joanna worked at OncoArendi Therapeutics SA, where she was responsible for the management of complex preclinical and clinical innovative drug development projects with budgets of approximately 15 million PLN.
Joanna is a certified Project Manager by IPMA PL and is a graduate of the Drug Registration Academy organised by the Polish Pharmaceutical Society.
Co-Founder and Leader of Altamira, a Warsaw-based deep-tech firm investing in Polish companies developing globally competitive technologies. For twelve years, he was a partner at Enterprise Investors, a leading private equity firm in Central and Eastern Europe, where he was responsible for the industrial goods and pharmaceutical sectors. Previously, he spent four years working in Warsaw and Paris at Boston Consulting Group.
Stanisław Knaflewski holds an MBA from INSEAD in Fontainebleau, a master’s degree in law from the University of Poznań and the College of Europe in Bruges, and completed the Visiting Fellow in Technology and Entrepreneurship program at MIT in Cambridge, USA.
A biotechnologist with a PhD in molecular biology, with extensive experience in managing research teams and drug discovery projects in oncology and pulmonology. She has worked at the Nencki Institute of Experimental Biology PAN, Celon Pharma, and OncoArendi Therapeutics, where she led innovative therapy projects, advancing them to late-stage preclinical and clinical research. She is a co-inventor of patents for new therapeutic molecules and an expert in intellectual property protection and technology transfer. Since 2020, she has been responsible for medical affairs and research collaborations at Philip Morris.
An experienced manager in comprehensive R&D project management, carried out in collaboration with the science and business sectors. For years, she has successfully built relationships between academia and industry, actively engaging in securing financial, industry, and strategic investors. She specializes in pre-incubation and incubation of innovative business ideas, as well as in establishing and developing startups, particularly in the area of corporate governance. She effectively develops and implements sales profitability plans, pricing analyses, and marketing and commercialization strategies, while managing teams and business processes.